Embecta Corp. (NASDAQ:EMBC) Shares Purchased by Jane Street Group LLC

Jane Street Group LLC increased its position in Embecta Corp. (NASDAQ:EMBC - Free Report) by 156.1% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 176,487 shares of the company's stock after purchasing an additional 107,567 shares during the period. Jane Street Group LLC owned 0.31% of Embecta worth $2,488,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the company. Quarry LP acquired a new stake in Embecta during the 3rd quarter worth $30,000. Garden State Investment Advisory Services LLC purchased a new stake in shares of Embecta in the third quarter valued at about $438,000. Verition Fund Management LLC boosted its stake in shares of Embecta by 45.3% during the third quarter. Verition Fund Management LLC now owns 17,682 shares of the company's stock worth $249,000 after buying an additional 5,511 shares during the period. Rockefeller Capital Management L.P. grew its holdings in shares of Embecta by 3.7% during the third quarter. Rockefeller Capital Management L.P. now owns 90,072 shares of the company's stock worth $1,270,000 after buying an additional 3,231 shares during the last quarter. Finally, Rubric Capital Management LP acquired a new position in Embecta in the 3rd quarter valued at about $15,306,000. 93.83% of the stock is owned by institutional investors and hedge funds.

Embecta Stock Up 0.8 %

NASDAQ EMBC traded up $0.16 during trading hours on Monday, hitting $20.39. 467,471 shares of the stock were exchanged, compared to its average volume of 414,608. The company has a market cap of $1.19 billion, a price-to-earnings ratio of 15.10, a price-to-earnings-growth ratio of 1.08 and a beta of 1.25. Embecta Corp. has a 12-month low of $9.93 and a 12-month high of $21.48. The stock has a 50-day moving average of $16.66 and a 200 day moving average of $14.97.

Embecta (NASDAQ:EMBC - Get Free Report) last issued its earnings results on Tuesday, November 26th. The company reported $0.45 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.40 by $0.05. Embecta had a negative return on equity of 18.54% and a net margin of 6.97%. The business had revenue of $286.10 million during the quarter, compared to the consensus estimate of $276.97 million. During the same period in the prior year, the business posted $0.59 EPS. The company's revenue for the quarter was up 1.5% on a year-over-year basis. On average, equities research analysts expect that Embecta Corp. will post 2.84 earnings per share for the current year.

Embecta Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, December 18th. Shareholders of record on Friday, December 6th were given a dividend of $0.15 per share. The ex-dividend date was Friday, December 6th. This represents a $0.60 annualized dividend and a dividend yield of 2.94%. Embecta's payout ratio is currently 44.44%.

Analyst Ratings Changes

Several research analysts have weighed in on EMBC shares. Morgan Stanley upgraded Embecta from an "underweight" rating to an "equal weight" rating and lifted their target price for the company from $13.00 to $20.00 in a research note on Monday, December 2nd. BTIG Research raised Embecta from a "neutral" rating to a "buy" rating and set a $26.00 price target for the company in a report on Wednesday, November 27th.

About Embecta

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.